This product includes the webinar and CME/CMLE credit


Speaker

Eric H. Bernicker, MD

Moderator

Christopher R. Gilbert, DO

Description:

Targeted therapies for advanced lung cancers continue to expand rapidly. Viewers of this presentation will get an overview of the latest developments in the management of oncogene-addicted lung cancers and the need for close collaboration between medical oncologists and pathologists to make sure that patients receive optimal therapy.

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: December 31, 2020

Maximum CME/CMLE credit available: 1.0

Supported by an educational grant from AstraZeneca   


How to claim credit: To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey. To access the online survey, click "Submit credit" on the course homepage, or click on "My Credit" on the menu to the left.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

* You may not submit SAMs and CME/CMLE credit for the same content.


You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 
Course Information
Course Date:
June 20, 2018
Course Objectives
  • Explain how targeted therapies are selected for patients with advanced adenocarcinoma of the lung.
  • Discuss the need for repeat biopsies upon progression so that therapies that target mechanisms of acquired resistance can be appropriately utilized.
Pre-Test for Best Practices in NSCLC Small Specimen Collection for Clinicians (+CME/CMLE)
Best Practices in NSCLC Small Specimen Collection for Clinicians
Post-Test for Best Practices in NSCLC Small Specimen Collection for Clinicians (+CME/CMLE)
QA Session
How to Claim CME/CMLE
Individual topic purchase: Selected
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
CMLE: 1.00
Products
NSCLC2 +CME/CMLE
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00